Evidence map›Paper›PMID 38366910›Full record

ArticleEpilepsia open2024

Causes and prognosis of adults experiencing a first seizure in adulthood: A pilot cohort study conducted in five countries in Latin America.

Arturo Carpio, Carla Salgado, Daniela DiCapua, Agnes Fleury, Roberto Suastegui, Brenda Giagante, Ledda Aguilera, Alonso Quijada, Lilia Nuñez, Manuela Villanueva and 5 more

Open access · goldAbstract read
In one paragraph

Article in Epilepsia open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 6 countries.

Arturo CarpioSchool of Medicine, University of Cuenca, Cuenca, Ecuador.ORCID https://orcid.org/0000-0002-5821-6379
Carla SalgadoFacultad de Medicina, Universidad de Azuay, Cuenca, Ecuador.
Daniela DiCapuaHospital Eugenio Espejo, Ministerio de Salud Pública, Quito, Ecuador.
Agnes FleuryDepartamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigación Biomédicas, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico.
Roberto SuasteguiInstituto Nacional de Neurología y Neurocirugia de, Ciudad de Mexico, Mexico.
Brenda GiaganteHospital Interzonal General de Agudos Prof. Dr. Rodolfo Rossi de La Plata, La Plata, Argentina.
Ledda AguileraHospital Clínico de la Universidad de Chile, Santiago de, Chile.
Alonso QuijadaHospital Clínico de la Universidad de Chile, Santiago de, Chile.
Lilia NuñezHospital 20 de Noviembre, Ciudad de Mexico, Mexico.
Manuela VillanuevaHospital de Alta Complejidad El Cruce "Néstor Kirchner", ENyS, CONICET, Florencio Varela, Argentina.
Noel Plascencia-AlvarezHospital 20 de Noviembre, Ciudad de Mexico, Mexico.
Pedro T Hamamoto FilhoBotucatu Medical School, UNESP - São Paulo State University, São Paulo, Brazil.ORCID https://orcid.org/0000-0001-6436-9307
Luis M PiedraHospital "José Carrasco" Instituto Ecuatoriano de Seguridad Social de Cuenca, Cuenca, Ecuador.
Carlos Silva-RosasHospital Clínico de la Universidad de Chile, Santiago de, Chile.
Elizabeth A KelvinDepartment of Epidemiology & Biostatistics, CUNY Graduate School of Public Health and Health Policy, City University of New York, New York, New York, USA.
Hospital Clínico de la Universidad de Chile · CLConsejo Nacional de Investigaciones Científicas y Técnicas · ARHospital Juárez de México · MXInstituto Nacional de Neurología y Neurocirugía · MXHospital de Especialidades José Carrasco Arteaga · ECMinisterio de Salud Pública · ECThe Graduate Center, CUNY · USUniversidad del Azuay · ECUniversidade Estadual Paulista (Unesp) · BRUniversity of Cuenca · EC

Funding

University of Cuenca, Ecuador 028-2021
6 · The paper itself

Abstract

There are limited data on first seizure (FS) among adults in low and middle-income countries. We describe findings from a prospective cohort study involving 180 adults presenting with seizures in emergency departments in five Latin American countries. Overall, 102 participants (56.7%) had acute symptomatic seizures (ASyS) while 78 (43.3%) had unprovoked seizures (UPS). Among patients with ASyS, 55 (53.9%) had structural causes, with stroke (n = 24, 23.5%), tumor (n = 10, 9.8%), and trauma (n = 3, 3%) being the most frequent. Nineteen patients (18.6%) had infectious causes, including four (4%) with meningoencephalitis, three (3%) neurocysticercosis, and two (2%) bacterial meningoencephalitis. Twenty patients (19.6%) had metabolic/toxic evidence, including four (4%) with uremic encephalopathy, two (2%) hyponatremia, and three (3%) acute alcohol intoxication. Immune dysfunction was present in seven (7%) patients and neurodegenerative in two (2%). Among participants with UPS, 45 (57.7%) had unknown etiology, 24 (30.7%) had evidence of structural disorders (remote symptomatic), four (5%) were related to infectious etiology (>7 days before the seizure), and five (6.4%) had genetic causes. During the 3- and 6-month follow-up, 29.8% and 14% of patients with UPS, respectively, experienced seizure recurrence, while 23.9% and 24.5% of patients with ASyS had seizure recurrence. Longer follow-up is necessary to assess seizure recurrence for patients with ASyS after the acute cause is resolved and to determine the 10-year risk of recurrence, which is part of the definition of epilepsy. PLAIN LANGUAGE SUMMARY: We monitored 180 adults who presented with their first seizure in emergency departments across five Latin American countries. Among these patients, 57% had acute symptomatic seizures, with structural causes such as stroke (23%), infection (17%), or tumor (10%) being more prevalent. Among the 43% with unprovoked seizures, 58% showed no identifiable acute cause, while 6.4% were due to genetics. Within 3 months after their initial seizure, 26.6% of individuals experienced a second seizure, with 11.9% continuing to have seizures in Months 3-6. Between Months 3 and 6, an additional 20% of patients encountered a second seizure. Research is needed to better understand the cause and prognosis of these patients to improve outcomes.

Indexed as

MeningoencephalitisNeoplasmsStrokeAdultCohort StudiesHumansLatin AmericaPilot ProjectsPrognosisProspective StudiesRecurrenceSeizuresacute symptomatic seizuresepilepsyetiologyfirst seizureneurocysticercosis

Identifiers

PMID38366910
PMCPMC10984322
OpenAlexW4391897053

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.